• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

EQL Pharma

23.90 SEK

+3.24 %

Less than 1K followers

EQL

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+3.24 %
+2.36 %
-56.55 %
-59.63 %
-58.65 %
-73.99 %
-19.53 %
-32.87 %
+344.67 %

EQL Pharma operates in the pharmaceutical industry and focuses on the development, manufacturing and distribution of generic medicines. The company's products are aimed at healthcare institutions and patients who need cost-effective treatment options. The business is global with a primary presence in Europe, North America and Asia. EQL Pharma was founded in 2006 and is headquartered in Lund, Sweden.

Read more
Market cap
705.76M SEK
Turnover
467.67K SEK
Revenue
432.66M
EBIT %
11.25 %
P/E
56.9
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
7/8
2026

Interim report Q1'27

20/8
2026

General meeting '26

5/11
2026

Interim report Q2'27

Press release2026-06-15 11:18

EQL Pharma: Metenaminhippurat (varumärket Cystohipp©) har lanserats i Tyskland

EQL Pharma
Press release2026-06-15 11:18

EQL Pharma: Methenamine hippurate (brand name Cystohipp©) has been launched in Germany

EQL Pharma
Third party research2026-05-15 07:13

EQL Pharma: Kostnaderna tilltar - Analysguiden

EQL Pharma levererade ett nytt försäljningsrekord under det fjärde kvartalet, men kvartalet präglades samtidigt av pressade marginaler, leveransproblem och ökade logistikkostnader. Flera engångsposter och en svagare guidning framåt gör att tillväxtcaset...

EQL Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2026-05-13 11:20

Analysguiden: ANALYS EQL Pharma: Kostnaderna tilltar

EQL Pharma
Press release2026-05-13 09:00

Kalqyl: EQL Pharma: Rapportkommentar Q4'25/26

EQL Pharma
Press release2026-05-12 13:45

Kalqyl: EQL Pharma: VD-intervju med Axel Schörling om Q4'25/26

EQL Pharma
Press release2026-05-11 07:16

DNB Carnegie Access: EQL Pharma: Near-term reset; solid execution needed to rebuild the case

EQL Pharma
Press release2026-05-08 09:17

DNB Carnegie Access: EQL Pharma: Better-than-feared Q4 overshadowed by cautious outlook

EQL Pharma
Regulatory press release2026-05-08 07:00

Bokslutskommuniké april 2025 - mars 2026

EQL Pharma
Regulatory press release2026-05-08 07:00

Year-end Report April 2025 - March 2026

EQL Pharma
Press release2026-04-27 13:12

EQL Pharma in process of recruiting new Chief Supply Chain Officer (CSCO)

EQL Pharma
Press release2026-04-27 13:12

EQL Pharma i process att rekrytera ny Chief Supply Chain Officer (CSCO)

EQL Pharma
Press release2026-04-22 13:01

Inbjudan till presentation i samband med EQL Pharmas Bokslutskommuniké, fjärde kvartalet, 2025/26

EQL Pharma
Press release2026-04-22 13:01

Invitation to presentation in connection with EQL Pharma's year-end report, fourth quarter, 2025/26

EQL Pharma
Press release2026-04-20 06:58

DNB Carnegie Access: EQL Pharma: Recovery continues, but near-term headwinds – Q4 preview

EQL Pharma
Press release2026-03-27 16:48

EQL Pharmas VD säljer aktier för att finansiera kapitalvinstskatt från optionsinlösen

EQL Pharma
Press release2026-03-27 16:48

EQL Pharma CEO sells shares to finance capital gains tax from option redemption

EQL Pharma
Press release2026-03-25 10:36

EQL Pharma: Mellozzan® (melatonin) har blivit godkänt i Italien

EQL Pharma
Press release2026-03-25 10:36

EQL Pharma: Mellozzan® (melatonin) has been approved in Italy

EQL Pharma
Regulatory press release2026-02-12 13:22

EQL Pharma: Valberedning inför årsstämman 2026

EQL Pharma